B7-33 — research reference, shipped from Colombia

Presentations and visible prices

The price above is the public value per vial. Availability and batch documentation are confirmed before the quotation is accepted.

B7-33 within the relaxin family

Relaxin-2 is the protein from which B7-33 is derived as a single-chain fragment. That structural lineage is what distinguishes this reference from others in the same catalog that are also grouped under research peptide compounds but come from different families: gastric fragments, thymosin fragments, or metal tripeptides. The name B7-33 is not a commercial brand; it is the code by which the technical literature identifies this specific fragment, and it should be recorded the same way in any institutional request so that it matches the quote, the label, and the receiving document.

This structural classification does not replace the analytical verification of an actual lot. Describing B7-33 as derived from relaxin-2 states which family the sequence published in the catalog comes from; it does not certify that a specific vial meets that identity — that is what the corresponding lot's certificate does. Until that evidence is requested and reviewed, the classification serves as a catalog reference, not as confirmed analytical data for the unit received.

A single peptide in a catalog of blends

The tissue-signaling category where B7-33 sits is largely populated by blends of several peptides in a single vial: the combination of BPC-157, TB-500, and GHK-Cu, and the version that adds KPV to those three. B7-33 is not a blend: it is a single reference, with a single declared sequence, with no additional components to add to the label. That difference in commercial design is relevant to the catalog, because a blend vial splits its cost across several components and B7-33's does not.

Before approving a quote that includes B7-33, it is worth checking its price directly in this page's commercial block, without assuming it matches that of a blend or of an individual component in the same category.

The two presentations and what they mean in lyophilized powder

B7-33's two presentations, 2 mg and 10 mg, are declared by mass, not by volume. Under the criterion the catalog already applies, a specification in milligrams corresponds to a lyophilized powder packaged in a vial, while a specification in milliliters corresponds to an already-prepared solution. B7-33 falls into the first group: both presentations arrive as powder, not as a ready liquid, and that physical form is what determines how the vial is stored and handled at the receiving laboratory — not a detail this listing needs to invent case by case.

Choosing between the 2 mg and 10 mg presentations is, above all, a decision about the amount of material per vial and the reference price tied to that amount, not a decision about how the compound is used. The purchasing laboratory sets its own internal protocol for handling the lyophilized powder once received; this listing does not replace or describe that protocol, and limits itself to stating the presentation as it appears in the catalog.

The Janoshik certificate for the B7-33 lot

The certificate of analysis for B7-33 is issued by Janoshik Analytical, per lot, using two distinct techniques: HPLC for purity and mass spectrometry for identity. These are two separate questions, and the document answers them separately. This listing does not turn that documentary availability into a published purity figure, because a percentage belongs to a specific lot and not to the reference in general; until that document is in hand, the correct figure is pending, not an estimate.

The COA is handled upon institutional request and subject to documentary availability. Upon receiving it, it is worth confirming that the lot identified on the certificate matches what physically arrives, and that the reference name is the same B7-33 named in the original request. CAS number, molecular formula, molecular weight, and full sequence do not appear on this listing because no specific documentary support for them exists today; they remain visibly pending until that support exists.

Cold storage and shipping to Bogotá or the rest of the country

The documentation applicable to the B7-33 lot defines its storage; the catalog's technical block currently states a range of 2–8 °C, protected from light. Preparing that storage space before the package arrives, rather than after, keeps the vial from sitting without a defined location in the gap between delivery and the laboratory's internal registration.

Shipping rates to Bogotá and to other destinations within the country are published on the site's shipping information page, not on this listing. Those figures cover transport, not the reference itself, and are confirmed, along with the estimated delivery time, during the quote, since timing depends on the destination and on coordination with the buyer rather than on a fixed value published in advance. Outside Colombia, this reference ships to 5 countries (Costa Rica, Ecuador, United States, Mexico and Puerto Rico), from US$57; the rate for each country is listed on the site's international shipping page.

From the institutional quote to the lot's file

An order for B7-33 is logged first, confirmed in writing in the institutional quote — with presentation, price, destination, and payment method — and only then is payment coordinated. This order lets whoever approves the expense review each element before moving funds, instead of reconstructing it later from scattered messages.

The complete purchase file brings together the request, the accepted quote, proof of payment, shipping confirmation, the receiving record, and the lot's COA when it was requested. If a document does not yet exist, the file shows it as pending rather than marking it as resolved; that is the same discipline applied across the rest of Peptidos Colombia's technical catalog.

Frequently asked questions about B7-33